Bringing a food product, a medicine, a medical device, a cosmetic, a herbal supplement or a household chemical onto the Thai market is, in legal terms, a regulated act of market entry that the Thai Food and Drug Administration controls from end to end. No product within its jurisdiction may lawfully be manufactured for sale, imported for sale, advertised or distributed in Thailand without prior authorisation under the relevant statute, and the agency's enforcement powers reach the company, its directors, the local representative and the customs broker. For foreign manufacturers and Thai importers alike, success in this market depends less on the quality of the product than on the discipline of the regulatory file.

This guide explains, in practical legal terms, what the Thai FDA does, which statutes it enforces, how each product family is classified and registered, what the timelines and obligations look like, and where foreign companies most often go wrong. The references throughout point to the primary statutes (the Food Act, Drug Act, Medical Device Act, Cosmetics Act, Herbal Product Act and Hazardous Substances Act), to the Ministerial Notifications issued under them, and to the Thai FDA's own e-submission portal at privus.fda.moph.go.th and English-language resource at en.fda.moph.go.th.

A Quick Map of the Thai FDA's Legal Authority

The Thai Food and Drug Administration is a department-level agency of the Ministry of Public Health (MOPH) with headquarters in Nonthaburi. It was established in 1974 and consolidated into a single agency the previously dispersed regulation of food, drugs, cosmetics and toxic substances. The Thai FDA's mandate is delivered through specialised bureaus (the Bureau of Food, the Bureau of Drug Control, the Bureau of Medical Devices, the Bureau of Cosmetics and Hazardous Substances and the Bureau of Herbal Medicine), supported by Provincial Public Health Offices that act as decentralised filing points for cosmetic notifications and many food licences for upcountry premises.

For a foreign company, three structural rules are non-negotiable. The product must be filed under the correct statute; filing a medical device dossier when the product is in fact a drug is one of the most common reasons for rejection or post-market enforcement. The licence holder must be a Thai-incorporated juristic person with a real, inspectable place of business in Thailand; foreign companies cannot directly hold a Thai FDA licence in their own name. And every step of the process now runs through the FDA's e-submission system, which means that the digital signature of the legally authorised director, the address of record at the Department of Business Development, and the data on the licence application must all match.

The Statutory Pillars of Thai FDA Regulation

The Thai FDA enforces six core statutes, supplemented by Ministerial Regulations and FDA Notifications issued under them.

The Drug Act, Food Act, Cosmetics Act and Herbal Product Act are administered by the Thai FDA alone. The Medical Device Act is administered by the Thai FDA in coordination with the Department of Medical Sciences for laboratory testing. The Hazardous Substances Act is administered jointly with several other agencies, with the Thai FDA responsible for the substances used in households and public health (such as mosquito coils, certain disinfectants, and some sanitising agents). The Narcotics Code B.E. 2564 (2021) and Psychotropic Substances Act sit alongside the Drug Act for controlled substances and are co-enforced with the Office of the Narcotics Control Board.

Food Regulation Under the Food Act B.E. 2522

The Four Food Risk Groups

The Food Act and the Notifications of the Ministry of Public Health issued under it classify food into four groups, each with a distinct filing pathway.

The four-group system, anchored in the Food Act and operationalised by Ministerial Notifications such as MOPH Notification No. 367 on labelling and a long series of product-specific Notifications, is the foundation of every food filing in Thailand.

Manufacture and Import Licences for the Place of Business

Separately from product-level registration, every food business operating at scale needs a place-of-business licence tied to the relevant premises.

• Sor.Bor.1 is the licence to manufacture food, issued under Section 14 of the Food Act, valid for three years.
• Sor.Bor.3 is the licence to import food for sale, issued under Section 15 of the Food Act, valid for three years.

The licences attach to the address (factory or warehouse) and to a defined list of products. Adding a new product line normally requires an amendment, and operating from an address other than the licensed premises is itself a breach of the Food Act.

Specifically Controlled Food Registration and Label Approval

For Specifically Controlled Food, the operator submits the formulation, the production method, the food quality analysis and the proposed label through the Thai FDA's e-submission portal. On approval, the Thai FDA issues a food serial number (the "Or.Yor." number that consumers see on the package) and a label authorisation. The package, the marketing materials and the customs declaration must all carry the same registered identifying information; mismatches are a routine cause of detention at customs.

Drug Regulation Under the Drug Act B.E. 2510

The Drug Act, originally enacted in 1967 and amended on several occasions, governs every product sold for the prevention, diagnosis, treatment or relief of disease in humans or animals. It requires two layers of authorisation: a place-of-business licence for the operator (manufacturer, importer or seller) and a marketing authorisation (drug registration) for each individual product, evidenced by a Drug Registration Certificate issued in the name of the licence holder.

Categories of Medicines

The Drug Act distinguishes between modern drugs, traditional drugs, household remedies and veterinary drugs. Modern drugs are pharmaceuticals based on chemical or biological active ingredients, including small-molecule drugs, biologicals and vaccines. Traditional drugs are products that follow a traditional Thai or foreign formula and that are not within the scope of the Herbal Product Act. Household remedies are a narrow list of over-the-counter products designated by Ministerial Notification (such as menthol balms and certain mild antiseptics) which can be sold outside licensed pharmacies under restricted conditions. Veterinary drugs are regulated under the Drug Act in coordination with the Department of Livestock Development.

Marketing Authorisation for New Drugs

A "new drug" application for a modern pharmaceutical requires a complete ASEAN Common Technical Document (ACTD) dossier, which mirrors the structure of the international ICH CTD: Module 1 administrative information and prescribing information; Module 2 overviews and summaries; Module 3 chemistry, manufacturing and controls; Module 4 non-clinical study reports; Module 5 clinical study reports. The dossier is supported by a Certificate of Pharmaceutical Product (CPP) or equivalent reference-country approval, the manufacturing site GMP certificate, and Thai-language labelling and patient information.

Timelines vary considerably with the dossier type. A well-prepared generic drug application is typically approved in several months, while a new chemical entity can take 6 months to 2 years from filing, especially where the Thai FDA Subcommittee on New Drugs requires additional clarifications. The first registration of a new drug is granted as a conditional approval ("two-year safety monitoring") during which the marketing authorisation holder collects and reports post-market safety data. Unconditional registration is granted on the satisfactory conclusion of that period.

Good Manufacturing Practice (GMP) Inspections

The Thai FDA recognises GMP certificates issued by reference regulators, including PIC/S members, the US FDA, the EMA and Japan's PMDA. It nevertheless reserves the right to conduct on-site inspections of foreign manufacturing facilities, particularly for biologicals, sterile products and high-risk dosage forms. The Thai FDA's Drug Bureau publishes its current GMP-PIC/S guidance on the Thai FDA website. Failure to maintain GMP status, or any change of manufacturing site that is not promptly reflected in the marketing authorisation, suspends the validity of the registration.

Medical Device Regulation Under the Medical Device Act B.E. 2551

The Medical Device Act B.E. 2551 (2008) was substantially overhauled by the Medical Device Act (No. 2) B.E. 2562 (2019), which moved Thailand to a risk-based classification system aligned with the ASEAN Medical Device Directive (AMDD). The 2019 amendment also introduced three distinct regulatory pathways calibrated to the device's risk profile.

Risk-Based Classification

Classification depends on intended use, duration of contact with the body, invasiveness, the criticality of the device's function and (for IVDs) the public-health consequence of a false result. Borderline cases are common, and an applicant who chooses too low a class to expedite approval risks reclassification, withdrawal of the listing or notification, and a separate offence under the Act.

The Three Pathways: Listing, Notification, Licensing

Listing applies to Class 1 devices and is the lightest pathway. The applicant uploads a CSDT Lite (Common Submission Dossier Template, abbreviated form) and a self-declaration of conformity with the Essential Principles. A Listing Number is normally issued within a few weeks for a complete file. Notification applies to Class 2 and Class 3 devices and requires a fuller CSDT including clinical evaluation evidence and ISO 13485 quality management system evidence; the Thai FDA conducts a substantive review and a Notification Number is granted on completion. Licensing applies to Class 4 devices, parallels the new-drug pathway, and requires a complete CSDT supported by clinical investigation reports. A complete and well-prepared Class 4 file is typically approved in 6 to 12 months; complex and first-in-class devices can take longer.

Common Submission Dossier Template (CSDT)

The CSDT is the harmonised ASEAN format for medical device dossiers. Core sections cover device description and intended use, design and manufacturing information, GMP/ISO 13485 evidence, Essential Principles compliance with conformity routes, pre-clinical and clinical evidence, labelling and instructions for use (with mandatory Thai-language IFU), and the post-market surveillance plan. Adverse-event reporting timelines after registration are short: serious adverse events must be reported to the Thai FDA within 15 calendar days (or 48 hours where there is a public-health threat).

Cosmetic Regulation Under the Cosmetics Act B.E. 2558

The Cosmetics Act B.E. 2558 (2015) treats every cosmetic as a controlled product. There is no formal product registration as such; instead, every cosmetic must be notified to the Thai FDA before it is manufactured or imported for sale. The Cosmetic Control Group within the Bureau of Cosmetics and Hazardous Substances administers the regime.

The Notification Procedure

The applicant submits an electronic notification on the Thai FDA's e-submission portal, identifying the operator (which must be a Thai-incorporated juristic person and have a place of business in Thailand), the product type, the full ingredient list checked against the Cosmetic Ingredient Database, the country of manufacture and the proposed Thai-language labelling. For a clean filing, the electronic Notification Receipt is normally issued within one working day. The Receipt is valid for three years and is renewable by re-notification before expiry.

Specially Controlled Cosmetics

A small set of products is designated by Ministerial Notification as specially controlled because of higher safety risk. The most cited examples include hair dyes, hair-bleaching agents, products containing certain UV filters above prescribed concentrations, and antibacterial hand soaps containing controlled ingredients. These products require a closer pre-market review and the timeline is approximately 30 working days from a complete filing.

Place-of-Business Requirements and Cosmetic GMP

Manufacturers in Thailand must hold a manufacturing place certificate and comply with the ASEAN Cosmetic GMP standard adopted by the Thai FDA. Importers must hold an import place certificate. Both attach to a real Thai address that is open to FDA inspection. Cosmetics imported for personal use only and in small quantities fall outside the licensing regime but remain subject to the labelling and ingredient prohibitions of the Act.

Herbal Product Regulation Under the Herbal Product Act B.E. 2562

Before 2019 the regulation of herbal medicines drifted between the Drug Act and the Food Act, depending on whether a product made therapeutic or nutritional claims. The Herbal Product Act B.E. 2562 (2019) consolidated the regime under a dedicated statute administered by the Thai FDA. Once a product is properly classified as a herbal product and is registered, notified or listed under the Act, it is exempt from the Drug Act and the Food Act for the same product.

The Act recognises four categories. Listed herbal products are simple herbal preparations (single-herb teas, household herbal balms) that pose minimal risk; they are filed by listing and a listing receipt is issued. Notified herbal products are products with established safety profiles filed by notification. Registered formula herbal products are products with new formulations or non-traditional claims and they go through a full registration with formula, stability and (where relevant) clinical or toxicological data. Licensed herbal products are higher-risk herbal products manufactured or imported on a commercial scale and they require a manufacturing or import licence in addition to product registration.

A licence to manufacture, import or sell a herbal product is valid for five years from the date of issuance, and a Certificate of herbal product registration is valid for five years from the date of issuance, in each case renewable on application before expiry.

Hazardous Substances Regulated by the Thai FDA

The Hazardous Substances Act B.E. 2535 (1992) is implemented by several agencies. The Thai FDA is the responsible authority for the substances used in households and for public-health purposes (mosquito repellents, household disinfectants and certain pesticides). Substances are placed in one of four types according to risk.

The Local Representative Requirement for Foreign Companies

A foreign company cannot hold a Thai FDA licence directly. It must either incorporate a Thai juristic person (typically a Thai limited company under the Civil and Commercial Code) or appoint a Thai-incorporated entity to act as the Licence Holder or Marketing Authorisation Holder. The legal consequence is significant: the Thai entity, not the foreign manufacturer, becomes the regulatory counterparty and bears primary responsibility under the relevant statute.

A poorly drafted distribution or appointment agreement that does not allocate compliance responsibility, control of the dossier, ownership of the licence on termination, and indemnities can leave a foreign manufacturer dependent on a local distributor it cannot easily replace. The standard contractual protections include a dossier ownership clause requiring the local representative to transfer the dossier and any registration files to the foreign manufacturer or its nominee on termination, a regulatory letter of authorisation structured to allow the manufacturer to nominate a successor representative with the Thai FDA's consent, an assignment of the FDA licence trigger event in case of distributor breach, and a clear allocation of responsibility for adverse event reporting and recall management.

The Thai FDA E-Submission System

Since 2020, the Thai FDA has progressively migrated every product family onto its e-submission system, accessible at privus.fda.moph.go.th. The portal handles cosmetic notifications, food product registration and label approval, drug import permits, medical device CSDT submissions, herbal product filings and certain hazardous substance applications. From a legal standpoint the digital migration has three practical consequences.

Submission timelines are stricter. Deficiency letters must usually be answered within 30 days, failing which the file is deemed abandoned and the application must be re-filed and re-paid. Discrepancies between the e-submission record, the customs declaration, the product label and the marketing materials are now easy for the Thai FDA to detect, and inconsistencies are a frequent ground for refusal or post-market enforcement. And digital signatures by the legally authorised director are tied to the company affidavit on file with the Department of Business Development; a directorship change must therefore be reflected in the FDA portal before any further filing is accepted.

Penalties for Non-Compliance

Sanctions differ across the six core statutes but follow the same architecture: administrative measures (cease-and-desist orders, recalls, suspension or revocation of the licence, public warning), criminal liability (fines and imprisonment), and personal liability of corporate officers. Where a juristic person commits an offence, directors and officers in charge of the act or omission are deemed to have committed the offence unless they can prove that they took reasonable steps to prevent it; this is a recurring formulation across the Food Act, Drug Act, Cosmetics Act and Medical Device Act.

The exact figures are revised by amending Acts and the Ministerial Notifications issued under them. The Drug Act in particular has been the subject of further amendment proposals raising the maximum fines for counterfeit drug offences into the millions of baht, in line with international anti-counterfeit standards.

A Practical Compliance Roadmap

For a foreign company starting from scratch, the order of operations matters as much as any single document. The sequence below reflects the path most foreign manufacturers take from market entry to first lawful sale.

1. Confirm the regulatory category. Decide whether the product is food, drug, medical device, cosmetic, herbal product, or hazardous substance, applying the most stringent regime where the product straddles two categories.
2. Set up the Thai operating entity or appoint and audit a local representative. The entity must be active, registered with the Department of Business Development and have a real Thai place of business.
3. Obtain the place-of-business licence appropriate to the product (Sor.Bor.1 or Sor.Bor.3 for food, manufacturing or import licence for drugs, manufacturing place certificate for cosmetics, manufacturing or import licence for herbal products, etc.).
4. Prepare the product dossier in the correct technical format (CSDT for medical devices, ACTD for drugs, formula and stability for food and cosmetics, formula and stability data for herbal products).
5. File via the e-submission portal with all supporting documents in Thai or with a certified Thai translation, and pay the official application fee.
6. Respond to deficiency letters within the statutory window (commonly 30 days, sometimes shorter for urgent safety issues).
7. Review the granted licence and label carefully before printing artwork and importing stock, paying particular attention to claims, warnings and the FDA registration number layout required on Thai-language packaging.
8. Maintain post-market obligations, including adverse event reporting, batch records, GMP audits, and timely renewals (cosmetic notification three years, food licence three years, herbal licence five years, drug GMP audits as scheduled).

Common Pitfalls That Trigger Enforcement Action

The most frequent errors that lead to enforcement action are surprisingly avoidable. They include filing under the wrong statute (most often a borderline cosmetic-drug or food-drug claim), making claims on the label or in marketing collateral that exceed what the licence authorises (such as therapeutic claims on a food supplement), using a virtual-office address as the place of business, mismatched importer details between the customs declaration and the FDA record, posting product images on social media before the notification or registration is granted, and failure to renew the cosmetic notification (three years), the food licence (three years), or the herbal licence (five years) on time. Treating each renewal as a calendar event in a regulatory tracker, owned by a named compliance officer, is the single most effective preventive measure.

Why Engaging Local Legal Counsel Pays Off

The Thai FDA framework is technically sophisticated but procedurally predictable. The cost of qualified legal and regulatory support is typically dwarfed by the cost of a customs hold, a recall, or a criminal prosecution. The drafting of the local representative's contract is often where the most value is added, as getting that document right protects the dossier, the licence, and the brand from being held hostage by a local partner. Juslaws & Consult advises pharmaceutical companies, medical device manufacturers, cosmetic brands, food and beverage importers, and herbal product developers on the complete cycle of Thai FDA work, from regulatory classification and dossier preparation through licence applications, label review, advertising approvals, recall management and dispute resolution. If you are evaluating a market entry into Thailand or want a second opinion on a draft dossier or a distribution agreement, our team can review the documents, explain the practical risks, and help you secure the registered protections that the law actually provides.

Frequently Asked Questions on Thai FDA Compliance